Third Party Collaborations. 17.1 The Institutions may undertake work on the Research in collaboration with a Collaborator subject to this Clause 17. Notwithstanding Clause 2.5, the Institutions may also receive funds or any other means of support from a Collaborator for carrying out the research in accordance with this Clause 17.
17.2 The applicable Institutions shall, prior to commencing their collaboration with a Collaborator, enter into a written agreement with such Collaborator which is consistent with the obligations assumed under this Contract setting out, among other things: -
(a) the role of the Collaborator in the Research;
(b) the provision of cash or in-kind contributions by the Collaborator for the Research; and
(c) the work to be undertaken by the Collaborator and its scientific contributions.
17.3 All agreements with Collaborators must conform with the Collaboration Guidelines specified in Annex 3. For the avoidance of doubt, Collaborators are not entitled to receive (directly or indirectly) any or any part of the Funds. The Host Institution shall keep Grantor informed of the progress on the work under the collaboration through the Yearly Progress Reports and the Final Progress Report.
17.4 The Host Institution shall be responsible for providing Grantor with copies of the relevant collaboration agreement between the Collaborator and the applicable Institutions including all amendments, modifications or revisions thereto.
Third Party Collaborations. LeukoSite agrees that it will not assist any third party, nor permit any third party to use any of its technology, data, information or inventions (whether or not patentable), in connection with the research, development or commercialization of any compound that has a similar structure to a compound that at the later of (i) the time of discovery of such third party's compound or (ii) the date that LeukoSite is to become first involved in the research or development or commercialization of such third party compound is the subject of active research, development or commercialization by Warner or one of its licensees under this Agreement. The foregoing shall apply only for so long as such compound remains subject to active research, development, clinical development or commercialization by Warner or one of its licensees under this Agreement.
Third Party Collaborations. 8.4.1 The Minister hereby grants the Proponents the right to enter into third-party collaboration agreements (CA) for Work described in Schedule 2 provided that:
a) the total number of CAs does not exceed 10;
b) no CA shall exceed $2,000,000 in typical TPC Eligible Cost as indicated in Schedule 3 - Claims and TPC Project Cost Principles;
c) the aggregate value in Eligible Costs for all CAs remains lower than $10 million;
d) the Proponent complies with Subsection 6.8 of Schedule 1 - TPC General Conditions;
e) the other terms and conditions of this subsection are met.
8.4.2 The Minister hereby agrees to subordinate his rights relating to the Intellectual Property developed in the context of the third-party collaboration agreement with respect to Subsection 8.4.1, and the specific technology developed under that agreement.
8.4.3 The Proponents shall obtain the Minister's written prior consent when entering into third-party collaboration agreements not contemplated by Subsection 8.4.1 above.
8.4.4 Any default under para. 8.4.3 constitutes an event of default under this Agreement.
8.4.5 The Parties agree to exclude from this section 8.4 the intellectual property resulting from work aimed at modifying an arm's length third Parties' intellectual property when the work is essential for the Project and solely to achieve the interoperability with or the incorporation into the Proponent's resulting products; such occurrences shall be reported to the Minister on an annual basis.
Third Party Collaborations. (a) XxxXxxx agrees that individuals that will receive information from and engage with [*] or any of its Affiliates pursuant to [*], by and between BeiGene and [*], with respect to any proposed and/or approved [*] (as defined in the [*] Agreement) involving a proprietary product that would be a Distracting Product under this Agreement if developed by BeiGene (such individuals, the “Third Party Collaboration Personnel” and, each, a “Third Party Collaboration Person”, and such [*], a “Restricted Study”) shall not have access to any Amgen Proprietary Information or Confidential Information of Amgen without Amgen’s prior written consent. In no event shall any individual that is or has been a Designated Person or any BeiGene personnel that have had access to Amgen proprietary clinical, regulatory, and strategic information or data pertaining to Amgen’s global development and commercialization of the Products be classified as a Third Party Collaboration Person.
(b) BeiGene shall not provide any input, advice, feedback, comments, or guidance to [*] or its Affiliates in connection with any Restricted Study; provided, however, that the foregoing shall not restrict the Third Party Collaboration Personnel’s ability to provide comments to a proposed protocol for a Restricted Study to the extent such comments relate solely to patient safety.
Third Party Collaborations. In the event that a for-profit Third Party requests access or licenses to HIBM mouse or other Licensed Intellectual Property for internal research use, HRG may propose to UPI a grant of rights to such Third Party and UPI shall have the right, at its sole discretion, to decide whether to allow the grant of such research-use-only limited license.
Third Party Collaborations. 17.1 The Institutions may undertake work on the Research in collaboration with a Collaborator subject to the following conditions.
17.2 The Institutions and the Collaborators shall enter into a written agreement that is consistent with the obligations assumed under this Contract and that includes conditions about: -
(a) the role of the Collaborator in the Research;
(b) the provision of cash or in-kind contributions to the Research by the Collaborator; and
(c) the work to be undertaken by the Collaborator and its scientific contributions. The Institutions shall enter into the collaboration agreement with the collaborator before commencing the collaboration in respect of any part of the Research.
17.3 All agreements with Collaborators must conform with the Collaborator Guidelines specified in Annex 2. For avoidance of doubt, Collaborators are not entitled to receive (directly or indirectly) any portion of the Funds.
17.4 The Host Institution must ensure that A*STAR is kept informed of the progress on the work under the collaboration in the Yearly Progress Reports and the Final Report.
17.5 The Host Institution is responsible for providing A*STAR with copies of the relevant collaboration agreement between the Collaborator and the Institutions as well as all amendments, modifications or revisions thereto.
17.6 The Host Institution and each Partner Institution shall promptly inform A*STAR if any aspect of the Research is the product of or otherwise relates to results obtained from a previous collaboration and the terms and conditions of any encumbrances on the relevant Research IP which may adversely affect A*STAR’s rights under clause 16.
Third Party Collaborations. When the PARTIES enter into third party collaboration, as prescribed in paragraph 7.10 (Either Party Unable / Unwilling to Collaborate), Canada and eVS shall:
Third Party Collaborations. Subject to the terms and conditions of this Agreement, the Parties shall each have the right to enter into collaborations with third parties.
Third Party Collaborations. It is the intent of the Parties that IPR and Know-How in the Collaboration Field that is useful for Commercial Optimization and is acquired (by license, assignment or otherwise) under or generated within any Third Party Collaboration shall be, to the extent authorized by contract and permitted by applicable law, made available to the other Party as part of the Collaboration, during the Collaboration Term (and throughout the Term in respect of Collaboration IPR arising therefrom).
Third Party Collaborations. 17.1 The Institutions may undertake work on the Research in collaboration with a Collaborator subject to this Clause 17.
17.2 The applicable Institutions shall, prior to commencing their collaboration with a Collaborator, enter into a written agreement with such Collaborator which is consistent with the obligations assumed under this Contract setting out, among other things: -
(a) the role of the Collaborator in the Research;
(b) the provision of cash or in-kind contributions by the Collaborator for the Research; and
(c) the work to be undertaken by the Collaborator and its scientific contributions.
17.3 All agreements with Collaborators must conform with the Collaboration Guidelines specified in Annex 2. For the avoidance of doubt, Collaborators are not entitled to receive (directly or indirectly) any or any part of the Funds.
17.4 The Host Institution shall keep Grantor informed of the progress on the work under the collaboration through the Yearly Progress Reports and the Final Report.
17.5 The Host Institution shall be responsible for providing Grantor with copies of the relevant collaboration agreement between the Collaborator and the applicable Institutions including all amendments, modifications or revisions thereto.
17.6 The Institutions shall promptly inform Grantor if any aspect of the Research is the product of or otherwise relates to results obtained from a previous collaboration and the terms and conditions of any encumbrances on the relevant Research IP which may adversely affect Grantor’s rights under Clause 16.
